



Republic of the Philippines
DEPARTMENT OF HEALTH
OFFICE OF THE SECRETARY

07 July 2014

HON. ENRIQUE T. ONA

Secretary
Department of Health

Dear **Secretary Ona**:

The Formulary Executive Council (FEC) respectfully recommends the **disapproval** of the application for inclusion of **clopidogrel bisulfate 300mg film-coated tablet** because after evaluating the submitted documents, it was noted that there is a very limited use for the said medicine. For acute ischemic strokes, the usual initial dose is 75 mg (one or two tablets), which is followed by a maintenance dose of 75 mg per day. While based on the Clinical Practice Guidelines for the Management of Coronary Artery Disease, 300 to 600 mg is only required as a loading dose when rapid onset of action is needed. This is followed by a maintenance dose of 75 mg daily.

The proponent was informed of this recommendation and was given 30 days to submit additional documents for reconsideration. However, the pharmaceutical company failed to comply within the set deadline. Thus, the recommendation of the Council to disapprove the application still remains.

For your approval, Sir.

Very truly yours,

For the Formulary Executive Council

A handwritten signature in black ink, appearing to read "Kenneth Hartigan-Go", is written over a horizontal line.

KENNETH HARTIGAN-GO, MD, MD(UK), FPCP, FPSECP, FPSCOT, FICD, FACP
Co-Chair, Formulary Executive Council

Approved / Disapproved:

A handwritten signature in black ink, appearing to read "ET Ona", is written in a cursive style.

ENRIQUE T. ONA, MD
Secretary of Health